The DNA methyltransferase inhibitor 5-azacytidine has been shown to reduce methylation, promote differentiation and, finally, induce tumor regression in a patient-derived IDH1 mutant glioma xenograft animal model [70]. This evidence concerns the gene IDH1 and central nervous system cancer.